PKD2
MCID: PLY060
MIFTS: 51

Polycystic Kidney Disease 2 (PKD2) malady

Categories: Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Polycystic Kidney Disease 2

Aliases & Descriptions for Polycystic Kidney Disease 2:

Name: Polycystic Kidney Disease 2 54 12 66 29 13 14
Pkd2 12 66
Polycystic Kidney Type 2 Autosomal Dominant Disease 52
Autosomal Dominant Polycystic Kidney Disease 2 66
Polycystic Kidney Disease, Adult, Type Ii 12
Polycystic Kidney Disease Adult Type Ii 66
Adult Polycystic Kidney Disease Type 2 66
Polycystic Kidney Disease, Type 2 69
Adpkd2 66
Apkd2 12
Pkd-2 66

Characteristics:

HPO:

32
polycystic kidney disease 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 613095
Disease Ontology 12 DOID:0110859
MedGen 40 C2751306

Summaries for Polycystic Kidney Disease 2

UniProtKB/Swiss-Prot : 66 Polycystic kidney disease 2: A disorder characterized by progressive formation and enlargement of cysts in both kidneys, typically leading to end-stage renal disease in adult life. Cysts also occurs in the liver and other organs. It represents approximately 15% of the cases of autosomal dominant polycystic kidney disease. PKD2 is clinically milder than PKD1 but it has a deleterious impact on overall life expectancy.

MalaCards based summary : Polycystic Kidney Disease 2, also known as pkd2, is related to polycystic kidney disease 2, autosomal dominant and kidney disease, and has symptoms including renal insufficiency and polycystic kidney dysplasia. An important gene associated with Polycystic Kidney Disease 2 is PKD2 (Polycystin 2, Transient Receptor Potential Cation Channel), and among its related pathways/superpathways are Ca, cAMP and Lipid Signaling and Signal transduction_Erk Interactions- Inhibition of Erk. The drugs Candesartan and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney and liver, and related phenotypes are Decreased human cytomegalovirus (HCMV) strain AD169 replication and Increased cell migration

Disease Ontology : 12 A autosomal dominant polycystic kidney disease that has material basis in autosomal dominant inheritance of mutation in the PKD2 gene on chromosome 4q22.1.

Description from OMIM: 613095

Related Diseases for Polycystic Kidney Disease 2

Diseases in the Polycystic Kidney Disease family:

Polycystic Kidney Disease 2 Polycystic Kidney Disease, Adult Type I
Polycystic Kidney Disease 3 Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease 1, Autosomal Dominant Polycystic Kidney Disease 2, Autosomal Dominant

Diseases related to Polycystic Kidney Disease 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
id Related Disease Score Top Affiliating Genes
1 polycystic kidney disease 2, autosomal dominant 12.0
2 kidney disease 10.3
3 polycystic kidney disease 10.3
4 dicer1-related disorders 10.1 PKD1 PKHD1
5 autosomal dominant polycystic kidney disease 10.0
6 inclusion body myopathy with paget disease of bone and frontotemporal dementia 10.0 PKD1 PKHD1
7 kidney papillary necrosis 10.0 PKD1 PKD2 PKHD1
8 atrophic vulva 9.9 PKDREJ PKHD1 PRKD1
9 holoprosencephaly 8 9.9 PKD1 PKD2 PKD3 PKDREJ PRKD1
10 t-cell large granular lymphocyte leukemia 9.7 PKD1 PKD2 PKDREJ PKHD1 PRKD1
11 anemia, hemolytic, rh-null, regulator type 9.7 PKD1 PKD2 PKHD1 PRKCSH PRKD1
12 polycystic liver disease 9.7
13 liver disease 9.7
14 psoriasis susceptibility 13 9.5 PKD1 PKD2 PKHD1 PRKCSH PRKD1 SEC63
15 lung giant cell carcinoma 9.5 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2
16 gastrointestinal lymphoma 9.4 PKD1 PKD2 PKD2L1 PKD3 PKDREJ PKHD1
17 1q21.1 recurrent microdeletion 9.3 HAX1 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1
18 charcot-marie-tooth disease, type 1c 8.5 PKD1 PKD1L1 PKD2 PKD2L1 PKD2L2 PKDREJ
19 orofacial cleft 4 8.0 HAX1 MIR17 PDK2 PKD1 PKD1L1 PKD1L3

Graphical network of the top 20 diseases related to Polycystic Kidney Disease 2:



Diseases related to Polycystic Kidney Disease 2

Symptoms & Phenotypes for Polycystic Kidney Disease 2

Clinical features from OMIM:

613095

Human phenotypes related to Polycystic Kidney Disease 2:

32
id Description HPO Frequency HPO Source Accession
1 renal insufficiency 32 HP:0000083
2 polycystic kidney dysplasia 32 HP:0000113

GenomeRNAi Phenotypes related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.26 PRKD3 PKD2L1 PKD2L2 PRKD1
2 Increased cell migration GR00055-A-3 8.92 PKD1 PKD2 PRKD2 PRKD3

MGI Mouse Phenotypes related to Polycystic Kidney Disease 2:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.1 PKD1 PKD1L1 PKD2 PKHD1 PRKCSH SEC63

Drugs & Therapeutics for Polycystic Kidney Disease 2

Drugs for Polycystic Kidney Disease 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Candesartan Approved Phase 4,Phase 2 139481-59-7 2541
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
3
Cilnidipine Approved Phase 4,Phase 2 132203-70-4 5282138
4
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Angiotensin II Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7 65143 172198
13
Candesartan cilexetil Phase 4,Phase 2 145040-37-5 2540
14 calcium channel blockers Phase 4,Phase 3,Phase 2
15 Adrenergic Agents Phase 4
16 Adrenergic Antagonists Phase 4
17 Adrenergic alpha-Antagonists Phase 4
18 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3
19 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
20 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
21 Angiotensinogen Phase 4,Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
23 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Antihypertensive Agents Phase 4,Phase 3,Phase 2
27 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
28 Calcium, Dietary Phase 4,Phase 3,Phase 2,Early Phase 1
29 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
31 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
34 Protective Agents Phase 4,Phase 3,Phase 2
35 Autonomic Agents Phase 4,Phase 2
36 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Early Phase 1
37
Curcumin Phase 4 458-37-7 969516
38 Analgesics Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Anti-Inflammatory Agents Phase 4
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4
42 Antirheumatic Agents Phase 4
43 Prednisolone acetate Phase 4
44 glucocorticoids Phase 4
45 Neuroprotective Agents Phase 4
46 Immunoglobulins Phase 4
47 Prednisolone hemisuccinate Phase 4
48 Prednisolone phosphate Phase 4
49 Antiemetics Phase 4
50 Antilymphocyte Serum Phase 4

Interventional clinical trials:

(show top 50) (show all 82)
id Name Status NCT ID Phase
1 CCB Safety Study in Treatment of Hypertension of ADPKD Unknown status NCT00541853 Phase 4
2 Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease Completed NCT00414440 Phase 4
3 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
4 Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Recruiting NCT02494141 Phase 4
5 Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant Terminated NCT00596947 Phase 4
6 Sirolimus for Massive Polycystic Liver Unknown status NCT01680250 Phase 2, Phase 3
7 Open-Label Extension of LOCKCYST Trial Unknown status NCT00771888 Phase 2, Phase 3
8 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] Completed NCT01022424 Phase 3
9 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease Completed NCT02225860 Phase 2, Phase 3
10 Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00456365 Phase 3
11 Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00346918 Phase 3
12 Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Completed NCT00309283 Phase 3
13 HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A Completed NCT00283686 Phase 3
14 Effects of Somatostatin on ADPKD Heart Completed NCT02119013 Phase 2, Phase 3
15 HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B Completed NCT01885559 Phase 3
16 Effects of Somatostatin on Liver in ADPKD Completed NCT02119052 Phase 2, Phase 3
17 Lanreotide as Treatment of Polycystic Livers Completed NCT00565097 Phase 2, Phase 3
18 Octreotide in Severe Polycystic Liver Disease Completed NCT00426153 Phase 2, Phase 3
19 Open-Label Tolvaptan Study in Subjects With ADPKD Completed NCT01214421 Phase 3
20 Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD Completed NCT00428948 Phase 3
21 Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease Completed NCT01315795 Phase 2, Phase 3
22 Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02055079 Phase 3
23 Lanreotide In Polycystic Kidney Disease Study Recruiting NCT02127437 Phase 3
24 Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) Recruiting NCT01733459 Phase 3
25 Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency Active, not recruiting NCT01377246 Phase 3
26 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Active, not recruiting NCT02160145 Phase 3
27 Study of Lanreotide to Treat Polycystic Kidney Disease Active, not recruiting NCT01616927 Phase 3
28 Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Enrolling by invitation NCT02251275 Phase 3
29 Everolimus on CKD Progression in ADPKD Patients Terminated NCT01009957 Phase 2, Phase 3
30 Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency Terminated NCT01223755 Phase 2, Phase 3
31 Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy Terminated NCT00920309 Phase 2, Phase 3
32 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study Unknown status NCT00571909 Phase 2
33 Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD) Unknown status NCT00890279 Phase 2
34 Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control Unknown status NCT01932450 Phase 2
35 Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety Completed NCT00491517 Phase 2
36 Bosutinib For Autosomal Dominant Polycystic Kidney Disease Completed NCT01233869 Phase 2
37 Effect of the Aquaretic Tolvaptan on Nitric Oxide System Completed NCT02527863 Phase 2
38 Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00286156 Phase 1, Phase 2
39 Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKD Completed NCT00413777 Phase 2
40 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT01451827 Phase 2
41 Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT01336972 Phase 2
42 Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease Completed NCT02140814 Phase 2
43 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] Completed NCT00841568 Phase 2
44 Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Completed NCT01210560 Phase 2
45 Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Completed NCT02021110 Phase 2
46 Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) Recruiting NCT02558595 Phase 2
47 Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02656017 Phase 2
48 Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02697617 Phase 2
49 Feasibility Study of Metformin Therapy in ADPKD Recruiting NCT02903511 Phase 2
50 A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Active, not recruiting NCT01559363 Phase 1, Phase 2

Search NIH Clinical Center for Polycystic Kidney Disease 2

Genetic Tests for Polycystic Kidney Disease 2

Genetic tests related to Polycystic Kidney Disease 2:

id Genetic test Affiliating Genes
1 Polycystic Kidney Disease 2 29

Anatomical Context for Polycystic Kidney Disease 2

MalaCards organs/tissues related to Polycystic Kidney Disease 2:

39
Kidney, Liver

Publications for Polycystic Kidney Disease 2

Articles related to Polycystic Kidney Disease 2:

(show all 13)
id Title Authors Year
1
Characterization of the polycystic kidney disease 2 gene promoter. ( 25173570 )
2014
2
Multiple postnatal craniofacial anomalies are characterized by conditional loss of polycystic kidney disease 2 (Pkd2). ( 23390131 )
2013
3
Construction of a transgenic pig model overexpressing polycystic kidney disease 2 (PKD2) gene. ( 23315160 )
2013
4
[Polymorphisms of four microsatellite markers tightly linked with polycystic kidney disease 2 gene in Chinese]. ( 11836683 )
2002
5
Mutations of the human polycystic kidney disease 2 (PKD2) gene. ( 11438989 )
2001
6
A novel frameshift mutation (2436insT) produces an immediate stop codon in the autosomal dominant polycystic kidney disease 2 (PKD2) gene. ( 10727541 )
2000
7
Polymorphisms in the human autosomal dominant polycystic kidney disease 2 (PKD2) gene. ( 10369752 )
1999
8
Mutations in autosomal dominant polycystic kidney disease 2 gene: Reduced expression of PKD2 protein in lymphoblastoid cells. ( 10213643 )
1999
9
A novel frameshift mutation induced by an adenosine insertion in the polycystic kidney disease 2 (PKD2) gene. ( 9573526 )
1998
10
A translation frameshift mutation induced by a cytosine insertion in the polycystic kidney disease 2 gene (PDK2). ( 9175744 )
1997
11
Novel stop and frameshifting mutations in the autosomal dominant polycystic kidney disease 2 (PKD2) gene. ( 9402976 )
1997
12
Characterization of the exon structure of the polycystic kidney disease 2 gene (PKD2). ( 9286709 )
1997
13
Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2. ( 8591848 )
1996

Variations for Polycystic Kidney Disease 2

UniProtKB/Swiss-Prot genetic disease variations for Polycystic Kidney Disease 2:

66
id Symbol AA change Variation ID SNP ID
1 PKD2 p.Trp414Gly VAR_009195
2 PKD2 p.Ala356Pro VAR_011073
3 PKD2 p.Arg306Gln VAR_058822
4 PKD2 p.Arg322Gln VAR_058823 rs145877597
5 PKD2 p.Arg322Trp VAR_058824
6 PKD2 p.Arg420Gly VAR_058825
7 PKD2 p.Asp511Val VAR_058827 rs121918043
8 PKD2 p.Cys632Arg VAR_058828
9 PKD2 p.Arg807Gln VAR_058830 rs147654263
10 PKD2 p.Ala384Pro VAR_064394

ClinVar genetic disease variations for Polycystic Kidney Disease 2:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 PKD2 NM_000297.3(PKD2): c.1390C> T (p.Arg464Ter) single nucleotide variant Pathogenic rs121918042 GRCh38 Chromosome 4, 88046712: 88046712
2 PKD2 PKD2, 1-BP INS, 2160A insertion Pathogenic
3 PKD2 PKD2, 1-BP INS, 197_203C insertion Pathogenic
4 PKD2 NM_000297.3(PKD2): c.1139G> A (p.Trp380Ter) single nucleotide variant Pathogenic rs121918039 GRCh37 Chromosome 4, 88964429: 88964429
5 PKD2 NM_000297.3(PKD2): c.2224C> T (p.Arg742Ter) single nucleotide variant Pathogenic rs121918040 GRCh37 Chromosome 4, 88986631: 88986631
6 PKD2 NM_000297.3(PKD2): c.1213C> T (p.Gln405Ter) single nucleotide variant Pathogenic rs121918041 GRCh37 Chromosome 4, 88964503: 88964503
7 PKD2 PKD2, 1-BP INS, 693C insertion Pathogenic
8 PKD2 NM_000297.3(PKD2): c.1532A> T (p.Asp511Val) single nucleotide variant Pathogenic rs121918043 GRCh37 Chromosome 4, 88968006: 88968006
9 PKD2 PKD2, 2-BP DEL/1-BP INS, NT1934 indel Pathogenic
10 PKD2 NC_000004.11: g.88957372-?_89042944+?dup duplication Pathogenic GRCh37 Chromosome 4, 88957372: 88957372
11 PKD2 NM_000297.3(PKD2): c.305_306insGAG (p.Glu102_Val103insArg) insertion Pathogenic rs398122932 GRCh37 Chromosome 4, 88929190: 88929191
12 PKD2 NM_000297.3(PKD2): c.916C> T (p.Arg306Ter) single nucleotide variant Pathogenic rs200001068 GRCh37 Chromosome 4, 88959475: 88959475
13 PKD2 NM_000297.3(PKD2): c.691dupC (p.Leu231Profs) duplication Likely pathogenic GRCh38 Chromosome 4, 88019553: 88019553

Expression for Polycystic Kidney Disease 2

Search GEO for disease gene expression data for Polycystic Kidney Disease 2.

Pathways for Polycystic Kidney Disease 2

Pathways related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.43 PRKD1 PRKD2 PRKD3
2 10.67 PRKD1 PRKD2 PRKD3
3 10.55 PRKD1 PRKD2 PRKD3

GO Terms for Polycystic Kidney Disease 2

Cellular components related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.8 PKD1 PKD1L1 PKD2 PKD2L1 PKHD1
2 cilium GO:0005929 9.72 PKD1 PKD1L1 PKD2 PKD2L1 PKHD1
3 calcium channel complex GO:0034704 9.37 PKD1L1 PKD2L1
4 polycystin complex GO:0002133 9.26 PKD1 PKD2
5 cation channel complex GO:0034703 9.16 PKD1L3 PKD2L1
6 non-motile cilium GO:0097730 9.13 PKD1L1 PKD2 PKD2L1
7 ciliary membrane GO:0060170 8.92 PKD1 PKD1L1 PKD2 PKD2L1

Biological processes related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 peptidyl-serine phosphorylation GO:0018105 9.82 PKD1 PRKD1 PRKD2
2 single organismal cell-cell adhesion GO:0016337 9.8 PKD1 PKD1L1 PKHD1
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 HAX1 PRKD1 PRKD2
4 kidney development GO:0001822 9.73 PKD1 PKD1L3 PKD2 PKHD1
5 calcium ion transport GO:0006816 9.72 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1
6 liver development GO:0001889 9.71 PKD1 PKD2 PRKCSH SEC63
7 sphingolipid biosynthetic process GO:0030148 9.69 PRKD1 PRKD2 PRKD3
8 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.64 PRKD1 PRKD2
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.64 PRKD1 PRKD2
10 embryonic placenta development GO:0001892 9.63 PKD1 PKD2
11 positive regulation of CREB transcription factor activity GO:0032793 9.62 PRKD1 PRKD2
12 cytoplasmic sequestering of transcription factor GO:0042994 9.62 PKD1 PKD2
13 placenta blood vessel development GO:0060674 9.61 PKD1 PKD2
14 cellular response to acidic pH GO:0071468 9.6 PKD1L3 PKD2L1
15 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.59 PKD1 PKD2
16 mesonephric tubule development GO:0072164 9.58 PKD1 PKD2
17 positive regulation of endothelial cell chemotaxis GO:2001028 9.58 PRKD1 PRKD2
18 mesonephric duct development GO:0072177 9.57 PKD1 PKD2
19 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.56 PRKD1 PRKD2
20 renal system development GO:0072001 9.56 PKD1 PKD2 PRKCSH SEC63
21 sensory perception of sour taste GO:0050915 9.55 PKD1L3 PKD2L1
22 positive regulation of histone deacetylase activity GO:1901727 9.54 PRKD1 PRKD2
23 nitrogen compound metabolic process GO:0006807 9.54 PKD1 PRKCSH SEC63
24 calcium ion transmembrane transport GO:0070588 9.5 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2
25 metanephric ascending thin limb development GO:0072218 9.49 PKD1 PKD2
26 detection of nodal flow GO:0003127 9.48 PKD1L1 PKD2
27 detection of chemical stimulus involved in sensory perception of sour taste GO:0001581 9.46 PKD1L3 PKD2L1
28 protein kinase D signaling GO:0089700 9.33 PRKD1 PRKD2 PRKD3
29 detection of mechanical stimulus GO:0050982 9.17 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2
30 transport GO:0006810 10.19 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2 PKDREJ
31 ion transport GO:0006811 10 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2 PKDREJ

Molecular functions related to Polycystic Kidney Disease 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.83 PKD2 PKD2L1 PKD2L2 PKDREJ PRKCSH
2 ion channel binding GO:0044325 9.5 PKD1 PKD2 PRKCSH
3 alpha-actinin binding GO:0051393 9.4 PKD2 PKD2L1
4 muscle alpha-actinin binding GO:0051371 9.37 PKD2 PKD2L1
5 cation transmembrane transporter activity GO:0008324 9.26 PKD1L3 PKD2L1
6 calcium channel activity GO:0005262 9.17 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2
7 sour taste receptor activity GO:0033040 9.16 PKD1L3 PKD2L1
8 protein kinase C activity GO:0004697 9.13 PRKD1 PRKD2 PRKD3

Sources for Polycystic Kidney Disease 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....